September 1988
Volume 29, Issue 9
Free
Articles  |   September 1988
Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. III. Histopathology.
Author Affiliations
  • C B Camras
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.
  • A H Friedman
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.
  • M M Rodrigues
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.
  • B J Tripathi
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.
  • R C Tripathi
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.
  • S M Podos
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.
Investigative Ophthalmology & Visual Science September 1988, Vol.29, 1428-1436. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C B Camras, A H Friedman, M M Rodrigues, B J Tripathi, R C Tripathi, S M Podos; Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. III. Histopathology.. Invest. Ophthalmol. Vis. Sci. 1988;29(9):1428-1436.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Prostaglandins (PGs), or their derivatives, are potent ocular hypotensive agents which may prove useful in glaucoma therapy. PGF2 alpha (250 micrograms in 50 microliter saline) or epinephrine 2% solution (50 microliter) was topically applied twice daily for 2 weeks to one eye of six cynomolgus monkeys for each agent. Contralateral control eyes received their respective vehicles. By light microscopy, there was no evidence of inflammation, corneal changes, retinal pathology (including cystoid macular edema), or other adverse effects. Likewise, by electron microscopy of the peripheral cornea, anterior chamber angle, iris base and ciliary body, no differences were noted between treated and control eyes. Therefore, multiple dosing with PGF2 alpha in subhuman primate eyes did not result in notable histopathological changes that would contraindicate a clinical trial in glaucoma patients.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×